Clinical trial

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

NCT00400894

Drugs and interventions used in this trial

0 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

No interventions are currently published for this study in CureCurrent. View the original registry record below.

Study at a glance

Registry-backed

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

Design: OBSERVATIONAL · Status: UNKNOWN · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2005-09-01

PhaseN/A

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Benign Prostatic Hyperplasiaverified · MONDO: benign prostatic hyperplasia

Prostatic Intraepithelial Neoplasiaverified · MONDO: prostate intraepithelial neoplasia

Interventions

Sponsors & collaborators

ProteoSys AGlead sponsor

Charite University, Berlin, Germanycollaborator

University Hospital Tuebingencollaborator

Medical Centre, Ludwigshafen, Germanycollaborator

Medical University Innsbruckcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00400894 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.